This French Nursing Home Accepts Inmates Others Won't
Despite these needs, very few healthcare facilities in France are equipped to accommodate older, dependent former inmates. Currently, only two nursing homes accept individuals with a history of incarceration. One of them is the Saint Barthélemy nursing home in Marseille, affiliated with the Saint John of God Foundation. Its director, Olivier Quenette, spoke with Journal International de Medecine (JIM) , a Medscape Network platform, about the challenges and responsibilities involved in caring for this particularly vulnerable group.
How did your nursing home come to care for individuals coming out of the prison system? Is there a link to the philosophy of the Foundation that supports your facility?
It happened by chance. We were approached by a family member of a 61-year-old man who had just been released from prison and had no housing solution. We agreed to take him in.
The Foundation's philosophy is to support the most vulnerable — those who are invisible or without options. We're committed to unconditional acceptance, so we responded positively to what was, in this case, an urgent request.
Did the idea of accepting incarcerated individuals develop gradually from there?
Absolutely. In 2005, we visited the Saint John of God facility in Austria, which had created a correctional unit within a hospital. That inspired us to consider the needs of aging people in prison. We started to study the issue and built relationships with the prison system to understand how it works — its language, procedures, and requirements — to be able to integrate these individuals appropriately.
How many incarcerated or formerly incarcerated individuals do you currently care for? What is their legal status?
As of our latest count in June 2024, we had admitted 29 people, including two women, with ages ranging from 54.5 to 89.7 years — an average age of 69.9. Fourteen were on modified sentences with judicial oversight, three were on parole with electronic monitoring, and seven had medical sentence suspensions. Only one was released without support.
How do you ensure anonymity for residents with a history of incarceration?
We've chosen to uphold a right to be forgotten. What matters to us is that the individual has either served their sentence or is in the process of doing so. We do not share the reasons for a resident's incarceration with the care team. This is an ethical decision. It's up to the resident to disclose their background, if and when they choose.
Naturally, in today's digital age, media reports about certain cases are easy to find. We've encountered such situations. But after more than 15 years of admitting former inmates, this is no longer a sensitive issue within our facility. We treat each person as an individual — not as someone defined by a past offense. Others may choose to look into a resident's background, but for us, it holds no greater weight than any other part of their personal history. We treat it as confidential, much like medical information.
Are there specific medical characteristics that distinguish incarcerated or formerly incarcerated residents from others in your facility?
Our nursing home has a somewhat specialized profile; we primarily care for individuals who have experienced homelessness or who live with mental health conditions. Of our 245 beds, the majority are occupied by residents with nontraditional or complex life histories. The current average age is 74, and approximately 60% of residents are men. Most are enrolled in public social assistance programs.
One of the key challenges with formerly incarcerated residents is helping them unlearn institutional behaviors developed in prison and relearn how to live independently. We recognized early on that this group requires more frequent and intensive psychological support, as they tend to experience higher levels of anxiety. This is particularly true for younger residents, especially those under the age of 65, who also benefit from more structured daily activities.
To support their reintegration, we offer paid, meaningful activities that carry therapeutic, occupational, and social value within the facility's community. We also maintain close collaboration with correctional social workers (known in France as CPIPs, Conseillers Pénitentiaires d'Insertion et de Probation), who visit monthly to meet with both the former inmates and staff.
We've successfully supported the reintegration of several former residents; four have transitioned to independent living. These transitions always take place following a period of judicial supervision, but each resident leads the process, and we provide support every step of the way.
What psychological and psychiatric support do you provide?
Some residents have psychiatric conditions. We rely on private psychiatrists who also care for our other residents, and we ensure follow-up. Our in-house psychologists work closely with these individuals, especially during the admission period and the first few months. Some residents are also under mandatory psychiatric follow-up ordered during incarceration.
How do you coordinate medical care and judicial monitoring — for example, for residents with electronic ankle monitors?
Their medical care is the same as for any other resident. With their consent, they are assigned a private physician who manages their care, appointments, and testing. We handle transport logistics if needed. One resident took 2 years before leaving the facility, so we support them in rebuilding autonomy.
Those with ankle monitors are allowed to leave their rooms during specific times, managed in coordination with their probation officer.
Nursing homes often report difficulties in hiring healthcare staff. Does your facility face these challenges?
The healthcare labor market in our sector is undeniably tight. We face recruitment challenges in certain roles, particularly when it comes to coordinating physicians — a difficulty reported by more than 30% of nursing homes in France. However, for nursing and nursing assistant positions, we are currently able to meet about 95% of our staffing needs. While we are not experiencing acute shortages, there is ongoing pressure, and we must continuously recruit to anticipate potential vacancies and ensure continuity of care.
Have your staff received specific training to care for current or former inmates? Have any raised concerns?
No specific training has been provided for caring for formerly incarcerated individuals. As I mentioned, we focus first on the resident's primary condition — whether that be mental illness, physical illness, or a state of dependency. In our experience, residents with severe psychiatric histories — particularly those recently discharged from psychiatric hospitals — often present greater care challenges than former inmates.
That said, we do offer targeted training on geriatric mental health, though not programs specifically focused on the needs of former prisoners.
Regarding staff concerns, we addressed them through discussions with our internal multidisciplinary ethics committee. We made a deliberate choice not to create dedicated units for former inmates. Instead, they are integrated across all units. This approach has worked well. Even during our initial admissions, there were some questions, but no significant issues arose.
In principle, any prisoner can be granted release for medical reasons or if they are over the age of 70. Is this law effectively applied?
Not at all. As I recall, this provision was introduced in 2014 by then-Justice Minister Christiane Taubira. But in reality, many incarcerated individuals over 70 are unable to access release because no care facility is available to receive them. So, despite being on the books, the law remains difficult to apply in practice.
Medical parole is granted by a sentencing judge, based on clinical evaluations. However, it only becomes a viable option if a long-term care facility is willing and able to admit the individual. According to the DAP, roughly 80-90 older inmates in France each year would meet the criteria for such release. That is a relatively small number considering the total nursing home capacity nationwide. But the fear of recidivism, especially involving individuals convicted of sexual offenses, remains the primary barrier to placement.
France currently has only two nursing homes that accept former inmates — yours and one in Cuiseaux. Should more facilities follow this model? What are the barriers?
In addition to the facility in Cuiseaux, a nursing home in the Ardennes began accepting former inmates 2 years ago, and the French Red Cross has also shown interest in participating.
Progress is being made, but it remains slow and limited. The biggest barrier is stigma: the fear that someone who has committed a crime may reoffend. Facilities are concerned about how families will react, whether there are safety risks for other residents, and what staff will think.
These fears continue to prevent many nursing homes from accepting former inmates. Yet these individuals are often seriously ill and no longer capable of living independently in a prison setting. In some cases, their living conditions behind bars may even be incompatible with basic human dignity.
In collaboration with the Ministry of Justice and the DAP, we've presented our model to national networks of nursing home directors to encourage broader participation. I've also met with two large foundations that have committed to supporting these efforts. The idea is starting to gain traction, but significant challenges remain.
For older, dependent inmates who remain in prison, what improvements are needed in their medical care?
At a minimum, prisons need architectural modifications to better accommodate individuals with physical dependency. In addition, access to in-home nursing services must be significantly improved within prisons and detention facilities.
While a few pilot programs exist, the response time for initiating care is approximately four times longer than in the general population. The main barrier is financial.
In my view, the most practical solution would be for every nursing home in France to commit to accepting at least one inmate per year. If just 90 facilities nationwide did so, we could resolve this public health challenge.
At our facility, for example, we currently house former inmates from Bapaume Prison near Lille. Before being accepted here, they were denied admission by 40-50 nursing homes in their local region.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
6 minutes ago
- Forbes
When The Brain Remembers Cold, The Body Burns Fat
Anyone who has shivered through winter knows how powerfully the body responds to cold. But what if simply remembering the cold could trigger the same effect? Cold is one of the oldest forces our bodies have had to reckon with. For mammals, surviving it depends on a delicate coordination between the brain and the body's heat response systems, especially brown adipose tissue, a specialized fat that burns energy to generate heat. A new Nature study from Trinity College Dublin reveals that this ancient survival mechanism can be stored as a memory and reactivated on demand. Mice trained to associate a specific environment with a frigid 4°C chill later mounted the same full-body heat response when placed in that environment at a comfortable 21°C. Their metabolism surged, oxygen consumption increased and brown fat genes switched on: exactly as if they were back in the cold. The effect was traced to 'engram' neurons in the hippocampus, which encodes memory, and the hypothalamus, the brain's temperature-control center. These neurons stored the cold experience and, when activated, signaled the body to turn on its heat-generating systems. When scientists artificially stimulated these neurons with light, the cold-memory effect appeared instantly, even in warm conditions. Silencing them erased the effect entirely. Brown fat is emerging as a critical factor in metabolic health. People with more active brown fat tend to have better glucose control, healthier cholesterol levels and lower risk of obesity and cardiovascular disease. Current strategies to activate brown fat, such as extended cold exposure, are often uncomfortable and impractical. If humans share this memory-based mechanism, it could be possible to design interventions that activate brown fat through sensory cues, immersive environments or targeted brain stimulation, without subjecting people to prolonged cold. Such approaches could open new pathways for treating obesity, type 2 diabetes and age-related metabolic decline. For countless generations, survival hinged not just on fire and shelter, but on the body's ability to anticipate and withstand the freeze. Imagine an early human clan returning each winter to the same windswept valley. Long before the snow fell, the very memory of that place could prime their bodies for hardship, raising metabolism, warming the blood, preparing muscles to endure. Memory was not simply a story of what had happened. It was a tool for survival, reaching deep into the body's physiology. This ancient machinery has not disappeared. It lies within us still, silent but ready to be awakened. This study suggests that the brain's recollection of cold can act as a switch, turning on the metabolic furnace of brown fat even when the surrounding air is mild. In other words, the mind does not just recall the past; it rehearses it in the flesh. The implications stretch far beyond cold itself. Science has already shown that memories of stress can elevate blood pressure, while cherished experiences can bolster immunity. Now, temperature memories join this list, showing how the mind scripts the body's responses. Our inner life is not sealed off from our organs. It writes instructions that ripple through heart, liver, muscle and fat. The challenge ahead is both technical and imaginative. How might we safely harness these circuits? Could a sound, a smell or a virtual landscape serve as a key to unlock the body's hidden stores of resilience? Could physicians prescribe an environment or an experience in the same way they prescribe a pill? To do so would be to redefine medicine itself, turning memory from a passive archive into an active instrument of healing. Our memories, it turns out, are not ghosts of the past. They are levers of the present, tools we may one day learn to wield with precision. What began as an evolutionary trick to survive the cold may become a strategy to live longer, healthier lives. The story of memory is no longer only about who we are; it is about who we might yet become.
Medscape
35 minutes ago
- Medscape
Early Access to Weight Loss Jabs in NICE Diabetes Plan
People with type 2 diabetes (T2D) in England could be offered earlier access to newer treatments, including weight loss jabs, under draft guidance from the National Institute for Health and Care Excellence (NICE). The guidance, described as the 'biggest shake-up in care for a decade', would see a shift from a one-size-fits-all approach to a focus on personalised treatment to prevent heart failure, heart attacks, and other serious complications. Expanded Use of SGLT-2 Inhibitors The draft guidance recommends expanding access to sodium-glucose co-transporter-2 (SGLT-2) inhibitors, including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. Currently prescribed as a second-line option, SGLT-2 inhibitors would be available as a joint first-line treatment alongside metformin. They may also be used as monotherapy in patients intolerant to metformin. SGLT-2 inhibitors are once-daily tablets that selectively block the SGLT-2 cotransporter in the proximal renal tubule, responsible for reabsorbing about 90% of filtered glucose. This lowers the renal glucose threshold, increasing urinary glucose excretion and inducing mild osmotic diuresis. However, a 2024 NICE analysis of nearly 590,000 people with T2D in England found under-prescribing of these drugs, particularly among women, older adults, and Black patients. Only 20% of patients with atherosclerotic cardiovascular disease received SGLT-2 inhibitors, with prescribing rates declining in older age groups. NICE estimates that wider use of SGLT-2 inhibitors could save nearly 22,000 lives once uptake reaches 90%. Earlier Access to GLP-1 Agonists The draft guidance also recommends earlier use of glucagon-like peptide-1 (GLP-1) receptor agonists such as liraglutide or semaglutide. These drugs, previously reserved for later stages of disease, would be considered earlier in treatment for selected groups. NICE further supports wider adoption of digital health tools, including continuous glucose monitoring and community-based digital care. Personalised Treatment Approaches The guidance proposes tailored treatment strategies based on patient characteristics and comorbidities: Adults with cardiovascular disease should receive triple therapy (metformin, an SGLT-2 inhibitor, and a GLP-1 receptor agonist) Those with early-onset T2D (diagnosed before age 40) should receive dual therapy before considering a GLP-1 receptor agonist Patients with obesity or chronic kidney disease should have specific combinations based on their condition and kidney function, respectively. Adults with clinical frailty should start with metformin monotherapy. Professor Jonathan Benger, deputy chief executive and chief medical officer at NICE, said the draft guidance marks a 'significant evolution' in diabetes care. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes, and other serious complications before they occur,' he said. Burden of Diabetes in the UK Approximately 4.6 million people in the UK have diabetes, with 90% diagnosed with T2D. Diabetes UK estimates that a further 1.3 million may be undiagnosed. The condition costs the NHS £1 million per hour, with 60% of spending linked to complications. Each week, diabetes contributes to more than 930 strokes, 660 heart attacks, and nearly 2990 cases of heart failure. Douglas Twenefour, head of clinical at Diabetes UK, welcomed the draft guidance. 'The majority of people with T2D are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications,' he said. 'Tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease.' Waqaar Shah, a GP partner at Chatfield Health Care in London and chair of the NICE guideline committee, said that these recommendations 'could help reduce health inequalities while providing better outcomes for everyone'. Implementation and Safety The draft guidance remains open for public consultation until 2 October. NICE will review feedback before publishing final recommendations. The guidance aims to promote equitable access to recommended therapies, supported by local training initiatives. Healthcare professionals have also stressed the need for safe prescribing of SGLT-2 inhibitors, which carry risks including diabetic ketoacidosis (DKA). Before starting treatment, providers should assess whether patients have previously experienced DKA, have acute illness, or follow very low-carbohydrate or ketogenic diets.
Medscape
35 minutes ago
- Medscape
Do Women With Acute ACS Face Unnecessary Bleeding Risk?
A consensus statement from two European cardiology organizations contends antithrombotic treatment for myocardial infarction and angina overlooks sex differences that heighten bleeding risk in women. Compared with men, women treated for acute coronary syndromes (ACS) are at a greater risk for in-hospital bleeding related to invasive cardiac procedures and more long-term outpatient bleeding events, according to the statement from the European Association of Percutaneous Cardiovascular Interventions and the European Society of Cardiology Working Group on Thrombosis. Antithrombotic therapies such as heparin and fondaparinux used in invasive ACS procedures typically have a similar efficacy in women and men, but women have a higher bleeding risk of these agents, said Davide Capodanno, MD, PhD, professor of cardiology at the University of Catania, Catania, Italy, and co-author of the consensus statement. Some ways to reduce bleeding risk in women are to adjust antithrombotic dosing for body weight and kidney function, Capodanno told Medscape Medical News , and to opt for radial access over femoral access for percutaneous coronary intervention (PCI). 'Our paper shows that women still experience delays in diagnosis and treatment, receive excessive antithrombotic doses more often, and remain underrepresented in trials,' Capodanno said. 'All of this creates the need for clear, pragmatic, sex-informed recommendations.' Physiologic Differences Hormonal differences between men and women play an important role in bleeding risk. Estrogen promotes the production of prostacyclin, increases the availability of nitric oxide, and reduces platelet aggregation. These features might protect against the earlier onset of coronary artery disease, but fluctuations in hormonal status due to the menstrual cycle, use of oral contraceptives, menopause, and hormone replacement therapy can also influence thrombotic and bleeding risks. Sex differences in protease-activated receptor signaling pathways, smaller coronary artery sizes, and a cascade of other factors contribute to the greater risk for bleeding associated with ACS treatment (Figure). Although ACS typically affects postmenopausal women, the incidence is increasing in premenopausal women, whose bleeding risk is even more elevated because of lower platelet reactivity due to estrogen receptors on the platelet surface. Data from nearly 4000 women and 10,000 men undergoing PCI showed women younger than 50 years were four times more likely than men of the same age to experience major and minor bleeding events associated with stenting. Wanted: More Sex-Specific Data Women also often experience delays in the diagnosis of ACS and referral for invasive treatments, such as PCI, for their condition. Clinicians still lack strong evidence to help them address sex differences in clotting and response to anticoagulation, Capodanno suggested. Awareness is improving, but there's still work to be done. 'We simply don't have enough sex-powered data to guide all our decisions. Women remain underrepresented in clinical trials, which limits the strength of sex-specific evidence,' Capodanno said. 'We need to push for more equitable research by enrolling and retaining more women in clinical studies and ensuring that results are analyzed and published separately for men and women.' Sunil V. Rao, MD, lead author of the 2025 joint clinical practice guidelines on ACS from the American College of Cardiology and the American Heart Association, agreed. 'There are very few clinical trials of bleeding reduction that have strong female representation,' said Rao, deputy director of the Leon H. Charney Division of Cardiology and director of interventional cardiology at NYU Langone Heart in New York City. One such study, the SAFE-PCI for Women randomized trial Rao led, compared radial access and femoral access in women undergoing stenting. The research showed using radial instead of femoral access for the intervention reduces the risk for bleeding in women. 'We need more trials like this to help guide the clinical community on how to mitigate the risks of antithrombotic therapy in women,' Rao said. Take-Home: Male Isn't Norm How can individual clinicians adjust their practice? 'We recommend actively reducing bleeding risk — for example, using radial access whenever possible, using ultrasound guidance if femoral access is needed, and always avoiding overdosing by adjusting for weight and kidney function,' Capodanno said. Prompt treatment is key to avoid sex-related delays in starting antithrombotic medications. 'Also, be mindful of sex-specific presentations in ACS,' he added. Among these is myocardial infarction with nonobstructive coronary arteries, which includes spontaneous coronary artery dissection, responsible for 25%-35% of myocardial infarctions in women younger than 50 years. According to Rao, European guidelines are generally consistent with North American recommendations with respect to antithrombotic strategies for ACS. 'I don't think we can make strong recommendations to change practice just yet,' he said. 'The message really is to counsel patients, especially female patients, on the benefit-risk balance of antithrombotic therapy, to use evidence-based approaches to reduce bleeding risk — such as radial access — and to refer female patients for clinical trials when possible.' Capodanno reported payment for speaker fees and advisory board participation from Bristol Myers Squibb, Daiichi Sankyo, Novo Nordisk, Sanofi, and Terumo. Rao reported no relevant financial conflicts of interest.
